Rhumbline Advisers Hutchmed (China) LTD Transaction History
Rhumbline Advisers
- $109 Billion
- Q3 2024
A detailed history of Rhumbline Advisers transactions in Hutchmed (China) LTD stock. As of the latest transaction made, Rhumbline Advisers holds 7,709 shares of HCM stock, worth $133,828. This represents 0.0% of its overall portfolio holdings.
Number of Shares
7,709
Previous 7,553
2.07%
Holding current value
$133,828
Previous $129,000
16.28%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding HCM
# of Institutions
65Shares Held
6.88MCall Options Held
6.2KPut Options Held
1.1K-
Schroder Investment Management Group London, X02.92MShares$50.8 Million0.06% of portfolio
-
Allianz Asset Management Gmb H Munich, 2M1.32MShares$23 Million0.04% of portfolio
-
State Street Corp Boston, MA350KShares$6.07 Million0.0% of portfolio
-
Aia Group LTD Hong Kong, K3315KShares$5.48 Million0.17% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny310KShares$5.38 Million0.0% of portfolio
About HUTCHMED (China) Ltd
- Ticker HCM
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 172,955,008
- Market Cap $3B
- Description
- HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...